226 related articles for article (PubMed ID: 30424786)
1. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury.
Billin AN; Honeycutt SE; McDougal AV; Kerr JP; Chen Z; Freudenberg JM; Rajpal DK; Luo G; Kramer HF; Geske RS; Fang F; Yao B; Clark RV; Lepore J; Cobitz A; Miller R; Nosaka K; Hinken AC; Russell AJ
Skelet Muscle; 2018 Nov; 8(1):35. PubMed ID: 30424786
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
3. HIF-P4H-2 deficiency protects against skeletal muscle ischemia-reperfusion injury.
Karsikas S; Myllymäki M; Heikkilä M; Sormunen R; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
J Mol Med (Berl); 2016 Mar; 94(3):301-10. PubMed ID: 26452676
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
[TBL] [Abstract][Full Text] [Related]
6. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
[TBL] [Abstract][Full Text] [Related]
7. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway.
Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R
Skelet Muscle; 2016; 6():5. PubMed ID: 26949511
[TBL] [Abstract][Full Text] [Related]
8. The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
Zhou J; Li J; Rosenbaum DM; Zhuang J; Poon C; Qin P; Rivera K; Lepore J; Willette RN; Hu E; Barone FC
PLoS One; 2017; 12(9):e0184049. PubMed ID: 28880966
[TBL] [Abstract][Full Text] [Related]
9. Brain-targeted hypoxia-inducible factor stabilization reduces neonatal hypoxic-ischemic brain injury.
Kuan CY; Chen HR; Gao N; Kuo YM; Chen CW; Yang D; Kinkaid MM; Hu E; Sun YY
Neurobiol Dis; 2021 Jan; 148():105200. PubMed ID: 33248237
[TBL] [Abstract][Full Text] [Related]
10. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor.
Adams DF; Watkins MS; Durette L; Laliberté J; Goulet F; Debien E; Frazier KS; Mellal N; Chen L; Shi W; Thomas R; Hu E
Toxicol Pathol; 2020 Feb; 48(2):362-378. PubMed ID: 31640478
[TBL] [Abstract][Full Text] [Related]
11. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
12. HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice.
Chen RL; Ogunshola OO; Yeoh KK; Jani A; Papadakis M; Nagel S; Schofield CJ; Buchan AM
J Neurochem; 2014 Oct; 131(2):177-89. PubMed ID: 24974727
[TBL] [Abstract][Full Text] [Related]
13. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
14. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia.
HoWangYin KY; Loinard C; Bakker W; Guérin CL; Vilar J; d'Audigier C; Mauge L; Bruneval P; Emmerich J; Lévy BI; Pouysségur J; Smadja DM; Silvestre JS
Stem Cells; 2014 Jan; 32(1):231-43. PubMed ID: 24105925
[TBL] [Abstract][Full Text] [Related]
15. Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult.
Vogler M; Zieseniss A; Hesse AR; Levent E; Tiburcy M; Heinze E; Burzlaff N; Schley G; Eckardt KU; Willam C; Katschinski DM
Pflugers Arch; 2015 Oct; 467(10):2141-9. PubMed ID: 25578858
[TBL] [Abstract][Full Text] [Related]
16. Lipophilic modification enhances anti-colitic properties of rosmarinic acid by potentiating its HIF-prolyl hydroxylases inhibitory activity.
Jeong S; Park H; Hong S; Yum S; Kim W; Jung Y
Eur J Pharmacol; 2015 Jan; 747():114-22. PubMed ID: 25483211
[TBL] [Abstract][Full Text] [Related]
17. HIF-prolyl hydroxylases and cardiovascular diseases.
Sen Banerjee S; Thirunavukkarasu M; Tipu Rishi M; Sanchez JA; Maulik N; Maulik G
Toxicol Mech Methods; 2012 Jun; 22(5):347-58. PubMed ID: 22424133
[TBL] [Abstract][Full Text] [Related]
18. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
19. Prolyl hydroxylase domain 2 reduction enhances skeletal muscle tissue regeneration after soft tissue trauma in mice.
Settelmeier S; Schreiber T; Mäki J; Byts N; Koivunen P; Myllyharju J; Fandrey J; Winning S
PLoS One; 2020; 15(5):e0233261. PubMed ID: 32413092
[TBL] [Abstract][Full Text] [Related]
20. Reduction of obliterative bronchiolitis (OB) by prolyl-hydroxylase-inhibitors activating hypoxia-inducible transcription factors in an experimental mouse model.
Heim C; Motsch B; Jalilova S; Bernhardt WM; Ramsperger-Gleixner M; Burzlaff N; Weyand M; Eckardt KU; Ensminger SM
Transpl Immunol; 2016 Nov; 39():66-73. PubMed ID: 27590486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
